A variety of natural, synthetic, and semisynthetic compounds either activating or suppressing IRE1α, PERK, ATF6, or GRP78 has been tested for the treatment of breast cancer [7,106], thyroid cancer [8], and glioma/glioblastoma [107,108]. The gene discussed is ERN1; the disease is glioblastoma.